EXCLUSIVE MEMBER BENEFITS 4.9/5 Star Reviews Work directly with a licensed provider to review labs, symptoms, and build your custom protocol
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
Emerging technologies such as computational protein design and AI-driven antigen prediction could further accelerate the development of personalized nanovaccines, tailoring therapies to individual neoantigen profiles
In laboratory investigations, researchers found that NNMT overexpression correlates with obesity and metabolic dysfunction, while its inhibition produces remarkable metabolic benefits
Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men
Indeed, we are currently collecting data and biological samples from patients who have recovered from severe pneumonia and/or acute respiratory distress syndrome (ARDS) (ClinicalTrials.gov Identifier: NCT06083363)
